Temirazer

Temirazer is a combinational drug comprising of Tenofovir disoproxil fumarate 300 mg and Emtricitabine 200 mg. It is a fixed-dose combination (FDC) drug used for managing patients with HIV-1 infection and HIV-1 Pre-Exposure Prophylaxis (PrEP). Temirazer (Tenofovir disoproxil fumarate + Emtricitabine) is utilized in combination with other antiretroviral agents in adults and children weighing greater than 35 kgs.

Prior testing before initiating Temirazer (Tenofovir disoproxil fumarate + Emtricitabine)

• •  Testing for Hepatitis B viral infection

• •  Testing for chronic kidney disease

• •  Testing for HIV-1 PrEP

Based on the body weight and age of the patients, Temirazer (Tenofovir disoproxil fumarate + Emtricitabine) has varied dosage regimens. The recommended dosage is 1 tablet (Tenofovir disoproxil fumarate 300 mg + Emtricitabine 200 mg) which is taken orally with or without food wherein,

• •  For adults, 1 dose once daily is recommended

• •  For children over 12 years of age and weight greater than 35 kgs, the same dose is given

• •  For kidney failure patients (Creatinine clearance: 30-49 mL/min), 1 dose in every 48 hours is administered

• •  For HIV-1 uninfected adults, 1 dose once daily is recommended

• •  For PrEP, 1 dose once daily with safer sex practices can be employed

Warnings and precautions:

There are certain conditions wherein patients should understand all the necessary details like,

• •  Discontinuation of Temirazer (Tenofovir disoproxil fumarate + Emtricitabine) leads to severe acute complications in the liver with Hepatitis B viral infection

• •  There are chances of procuring acute kidney failure due to one of the components of the drug

• •  Do not use other drugs containing the same molecules (tenofovir disoproxil fumarate and emtricitabine) or other molecules (Efavirenz, Rilpivirine, and Lamivudine) alone or in combination

• •  In some advanced HIV infected patients, there are chances of inflammation occurring due to immune reconstitution syndrome

• •  Patients are seen with decreased bone mineral density (Weakened bones)

• •  In a few cases, the patients gain an excessive amount of lactic acid in the blood (lactic acidosis) which may lead to hepatoxicity

• •  Patients should confirm if they are negative for HIV-1 infection before starting the drug for HIV-1 PrEP therapy

• •  Use all possible contraceptive methods for preventing the transmission of new HIV-1 infection

Side-effects of Temirazer (Tenofovir disoproxil fumarate + Emtricitabine)

Most common side-effects in HIV-1 infected patients:

• •  Diarrhea

• •  Tiredness (Fatigue)

• •  Dizziness

• •  Atypical dreams

• •  Difficulty in sleeping (Insomnia)

• •  Depression

• •  Headache

• •  Rashes on the skin

• •  Nausea

Most common side-effects in patients who took the drug to reduce the risk of getting HIV-1 infection:

• •  Pain in the abdomen (stomach area)

• •  Loss of weight

• •  Headache

Note: Temirazer (Tenofovir disoproxil fumarate + Emtricitabine) may show other side effects too; consult your doctor for more information.